Every material Form 8-K Zimmer Biomet filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Zimmer Biomet Holdings, Inc. reported third quarter 2026 net sales of $2.063 billion, representing a 3.1% reported increase and a 3.7% increase on a constant currency basis. Diluted earnings per share were $1.00, down 13.8%, while adjusted diluted earnings per share were flat at $1.90. Following the broad-based performance, the company raised its full-year 2026 organic constant-currency revenue growth and adjusted EPS guidance.
Third quarter net sales reached $2.063 billion, up 3.1% on a reported basis.
Diluted earnings per share were $1.00, compared to $1.16 in the prior year period.
Adjusted diluted earnings per share were $1.90, matching the prior year period.
Full-year 2026 adjusted diluted EPS guidance was updated to a range of $8.50 to $8.60.
Zimmer Biomet said Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company effective September 30, 2026, as his position is restructured. Gary Campbell, Brian Hatcher and Bradley Kessler were promoted to new roles effective October 1, and the company reiterated its full-year 2026 financial outlook provided on August 5, 2026.
Kevin Thornal's position is restructured and he departs effective September 30, 2026, with severance under the Restated Executive Severance Plan.
Thornal's severance is a lump sum of twelve months of base salary plus target annual bonus, plus twelve months of COBRA premiums, conditioned on a general release.
Gary Campbell becomes President, Americas; Brian Hatcher becomes President, Recon, S.E.T., CMFT, Neuro and Biosurgery; Bradley Kessler becomes President, Americas – Robotics, Technology and Data, all effective October 1.
The company reiterated its full-year 2026 financial outlook provided on August 5, 2026.
Zimmer Biomet reported second-quarter 2026 net sales of $2.177 billion, up 4.8% from the prior year, and diluted earnings per share of $1.03, up 33.8%. The company raised its full-year 2026 reported revenue and adjusted diluted EPS guidance, and adjusted EPS for the quarter was flat at $2.07.
Q2 net sales of $2.177 billion rose 4.8% reported and 4.0% on an organic constant currency basis.
Q2 diluted EPS was $1.03, up 33.8%; adjusted diluted EPS was $2.07, consistent with the prior year period.
2026 reported revenue change guidance raised to 3.9% to 4.9% from 2.5% to 4.5%; adjusted diluted EPS guidance raised to $8.47 to $8.59 from $8.40 to $8.55.
Share repurchase expectation increased to up to $1 billion of common stock during fiscal year 2026.
Zimmer Biomet signed a new $1.5 billion five-year unsecured revolving credit agreement and a $1.25 billion 364-day unsecured revolving credit agreement, both dated June 26, 2026, with JPMorgan Chase Bank as administrative agent. The company said the borrowings will fund general corporate purposes and terminated its two prior revolving facilities dated June 27, 2025, which had no balance outstanding. The filing describes the new facilities as financing arrangements that carry covenants, including a maximum consolidated indebtedness to EBITDA ratio of 4.5 to 1.0.
Five-year facility of $1.5 billion matures June 26, 2031, with an uncommitted feature to increase it by up to $750.0 million
364-day facility of $1.25 billion matures June 25, 2027
Both agreements require a consolidated indebtedness to EBITDA ratio of no greater than 4.5 to 1.0
Prior 2025 facilities were terminated June 26, 2026; about $0.4 million in fees were paid in cash
Zimmer Biomet said Chief Financial Officer Suketu Upadhyay will resign effective April 28, 2026, to pursue a new professional opportunity. Controller and Chief Accounting Officer Paul Stellato will serve as interim CFO while the company searches for a permanent successor, and the company said Upadhyay's departure did not involve any disagreement on financial or operational matters.
Upadhyay's resignation is effective April 28, 2026; he informed the company on April 22, 2026.
Stellato, 51, has been Controller and Chief Accounting Officer since May 2022 and will hold both roles plus interim CFO.
Stellato's interim CFO pay includes a $550,000 annual base salary (prorated) and a 2026 target bonus of 70% of base salary.
Equity grants with a May 1, 2026 grant date include restricted stock units of about $750,000 and performance-based units of about $100,000.
Zimmer Biomet reported first-quarter 2026 net sales of $2.087 billion, up 9.3% from the prior year, and diluted earnings per share of $1.22, up 34.1%. The company raised its full-year 2026 adjusted diluted EPS guidance to $8.40-$8.55 from $8.30-$8.45, while its reported revenue change guidance of 2.5%-4.5% was unchanged. The company's goodwill impairment assessment is not yet complete, and any charge would change first-quarter GAAP net earnings.
Net sales $2.087 billion, up 9.3% reported and 2.9% on an organic constant currency basis
Diluted EPS $1.22 versus $0.91; adjusted diluted EPS $2.09, up 15.5%
2026 adjusted diluted EPS guidance raised to $8.40-$8.55 from $8.30-$8.45
Operating cash flow $359.4 million and free cash flow $245.9 million; $250 million of share repurchases in the quarter
Zimmer Biomet reported fourth-quarter 2025 net sales of $2.244 billion, up 10.9%, while GAAP diluted EPS fell 41.7% to $0.70; adjusted diluted EPS rose 4.8% to $2.42. For full-year 2025, net sales were $8.232 billion (up 7.2%) and GAAP diluted EPS was $3.55 (down 19.9%). The company guided 2026 reported revenue growth of 2.5% to 4.5% and adjusted diluted EPS of $8.30 to $8.45, and its board approved a repurchase authorization of up to $1.5 billion.
Q4 2025 net sales $2.244 billion, up 10.9% reported and 5.4% organic constant currency
Q4 GAAP diluted EPS $0.70 versus $1.20 a year earlier; Q4 operating profit $154.5 million versus $389.0 million
2026 guidance: reported revenue change 2.5% to 4.5%; adjusted diluted EPS $8.30 to $8.45 versus $8.20 in 2025
Board approved buyback of up to $1.5 billion starting February 9, 2026, with no expiration; $250 million repurchased in Q4 2025
Zimmer Biomet said Mark Bezjak, a named executive officer in its 2025 proxy statement, informed the company on January 8, 2026 that he will resign his employment and all officer positions effective January 16, 2026, to pursue another business opportunity. The filing notes he already ceased to be an executive officer on July 1, 2025, so the change is largely a formal exit. The filing does not name a successor.
Mark Bezjak notified the company on January 8, 2026 of his resignation.
Resignation takes effect January 16, 2026, covering his employment and all officer roles at the company and its affiliates.
Bezjak stopped being an executive officer on July 1, 2025, as previously reported.
The filing reports no financial results; its only exhibit is the Inline XBRL cover page file.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Zimmer Biomet filing is on SEC EDGAR ↗. 8-K briefs of other companies →